This article is part of MPR’s coverage of the American Academy of Ophthalmology 2019 Meeting, taking place in San Francisco, CA. Our staff will report on medical research related to eye disorders, conducted by experts in the field. Check back regularly for more news from AAO 2019.

SAN FRANCISCO – Brolucizumab demonstrated superior anatomic results and maintained best corrected visual acuity (BCVA) in patients with polypoidal choroidal vasculopathy (PCV) at week 96 of the HAWK study compared with aflibercept, according to data presented at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting, held October 12-15, 2019 in San Francisco, California.

HAWK was a phase 3, prospective, double-masked, multicenter trial that compared brolucizumab to aflibercept in 1078 patients with neovascular age-related macular degeneration (nAMD) for 96-weeks. Researchers further evaluated the efficacy and safety of brolucizumab among Japanese patients with PCV in the HAWK study (N=89 out of 1078). Patients received brolucizumab 3mg (n=20) or 6mg (n=39) every 8 or 12 weeks, or aflibercept 2mg (n=30) every 8 weeks after the first 3 monthly doses.

Results demonstrated the mean BCVA change from baseline was maintained for all treatment arms up to week 96. A greater proportion of PCV patients were maintained on brolucizumab 6mg compared with 3mg dosed at 12-week intervals (76.3% vs 70% at week 48; 68.1% vs 64.6% at week 96, respectively). Similarly, 93.5% of brolucizumab 6mg PCV patients who successfully completed the first 12-week interval remained on the dosing regimen until week 48; 89.3% who successfully completed treatment through week 48 remained on a 12-week interval through week 96.

Related Articles

With regard to anatomic results, fewer PCV patients experienced intra-retinal (IRF) and/or sub-retinal fluid (SRF) with brolucizumab 6mg compared with aflibercept at weeks 16, 48 and 96. In addition, a greater reduction in central subfield thickness (CST) was observed with brolucizumab 6mg vs aflibercept.

The overall safety profile of brolucizumab was consistent to aflibercept.

Researchers concluded, “Robust BCVA gains were observed in the PCV population, across all treatment arms. Brolucizumab monotherapy works well in typical AMD and PCV patients.”

Reference

Jaffe, GJ, et al. Comparison of the Efficacy and Safety of Brolucizumab versus Aflibercept in eyes with Polypoidal Choroidal Vasculopathy: 96-Week Results from the HAWK Study. The American Academy of Ophthalmology Meeting; October 12-15 2019.